STEMdiff™ SMADi Neural Induction Kit
Serum-free medium kit for highly efficient SMAD inhibition-mediated neural induction of human ES and iPS cells
-
STEMdiff™ SMADi Neural Induction Kit -
Label for STEMdiff™ SMADi Neural Induction Kit -
Label for STEMdiff™ SMADi Neural Induction Kit
More Views
Overview
STEMdiff™ SMADi Neural Induction Kit consists of a defined, serum-free medium and supplement for the highly efficient neural induction of human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells. This kit combines STEMdiff™ Neural Induction Medium (Catalog #05835) with STEMdiff™ SMADi Neural Induction Supplement, which directs differentiation by blocking TGF-β/BMP-dependent SMAD signaling, resulting in efficient neural induction of even hard-to-differentiate cell lines. Neural progenitor cells (NPCs) can be generated using STEMdiff™ SMADi Neural Induction Kit with either an embryoid body (EB) protocol or monolayer culture protocol. The resulting cultures are enriched for central nervous system (CNS)-type NPCs, which express SOX1, Nestin, and PAX6. NPCs generated using this kit can be passaged as single cells and expanded in STEMdiff™ Neural Progenitor Medium (Catalog #05833). The NPCs can also be differentiated into neurons and glia.
Advantages:
• Defined and serum-free
• Promotes efficient conversion of ES and iPS cells to CNS-type NPCs, and inhibits unwanted differentiation of non-CNS cell types
• Highly efficient neural induction of even hard-to-differentiate ES and iPS cell lines
• Improves efficiency of downstream differentiation into neurons and glia
• Compatible with both embryoid body and monolayer culture protocols for neural induction
• Enables reproducible differentiation of cell lines maintained in any TeSR™ family maintenance medium
• Convenient, user-friendly format and protocols
• Promotes efficient conversion of ES and iPS cells to CNS-type NPCs, and inhibits unwanted differentiation of non-CNS cell types
• Highly efficient neural induction of even hard-to-differentiate ES and iPS cell lines
• Improves efficiency of downstream differentiation into neurons and glia
• Compatible with both embryoid body and monolayer culture protocols for neural induction
• Enables reproducible differentiation of cell lines maintained in any TeSR™ family maintenance medium
• Convenient, user-friendly format and protocols
Components:
STEMdiff™ SMADi Neural Induction Kit (Catalog #08581)
STEMdiff™ Neural Induction Medium, 250 mL
STEMdiff™ SMADi Neural Induction Supplement, 0.5 mL
STEMdiff™ SMADi Neural Induction Kit, 2 Pack (Catalog #08582)
STEMdiff™ Neural Induction Medium, 2 x 250 mL
STEMdiff™ SMADi Neural Induction Supplement, 2 x 0.5 mL
Subtype:
Specialized Media
Cell Type:
Neural Cells, PSC-Derived; Pluripotent Stem Cells
Application:
Differentiation
Brand:
STEMdiff
Area of Interest:
Disease Modeling; Drug Discovery and Toxicity Testing; Neuroscience; Stem Cell Biology
Formulation:
Serum-Free
Related Products
-
STEMdiff™ Neural Induction Medium
Defined, serum-free medium for neural induction of human ES and iPS cells -
STEMdiff™ Neural Progenitor Medium
Medium for maintenance and expansion of neural progenitor cells derived from human ES and iPS cells -
Serum-free neurophysiological basal medium for improved neuronal function
Scientific Resources
Product Documentation
Document Type
Product Name
Catalog #
Lot #
Language
Educational Materials
(21)
Load More Educational Materials
Product Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Research Area
Workflow Stages for
Workflow Stages
Data and Publications
Data
Figure 1. STEMdiff™ SMADi Neural Induction Kit Supports Generation of Neural Progenitor Cells with High Levels of PAX6 and SOX1 Expression.
Neural progenitor cells (NPCs) can be generated from hPSCs cultured in mTeSR™1 or TeSR™-E8™ via embryoid body or monolayer protocol using the STEMdiff™ SMADi Neural Induction Kit. Resulting NPCs express CNS-type NPC markers PAX6 and SOX1.
Figure 2. STEMdiff™ SMADi Neural Induction Kit Supports Robust Neural Progenitor Cell Generation Across Multiple hPSC Lines.
Multiple human ES and iPS lines (cultured in mTeSR™1 or TeSR™-E8™) were subjected to the monolayer neural induction protocol. Cells were harvested after 7 days in culture and processed for immunostaining with PAX6, SOX1 and SOX10 antibodies. Cultures were imaged and quantified using the high content imager ImageXpress Micro, which counts positive nuclei across the entirety of the culture well. n=3 replicates per cell line. Data showed that neural progenitor cells produced using the STEMdiff™ SMADi Neural Induction Kit expressed very high levels of CNS-type markers PAX6 and SOX1, while the neural crest marker SOX10 was low to undetectable.
Figure 3. Neural Progenitor Cells Produced Using the Stemdiff™ SMADi Neural Induction Kit Support Highly Efficient Downstream Differentiation Into Neurons and Astrocytes.
Starting hPSCs were maintained in mTeSR™1 and differentiated using an embryoid body (EB) protocol. Resulting cells were differentiated using the STEMdiff™ Neuron Differentiation/Maturation Kits, STEMdiff™ Astrocyte Differentiation/Maturation Kits, and STEMdiff™ Dopaminergic Neuron Differentiation/Maturation Kits as per the respective protocols.
Publications
(11)
Stem Cell Reports 2017 MAR
Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells
Abstract
Abstract
Huntington disease (HD) is a dominant neurodegenerative disorder caused by a CAG repeat expansion in HTT. Here we report correction of HD human induced pluripotent stem cells (hiPSCs) using a CRISPR-Cas9 and piggyBac transposon-based approach. We show that both HD and corrected isogenic hiPSCs can be differentiated into excitable, synaptically active forebrain neurons. We further demonstrate that phenotypic abnormalities in HD hiPSC-derived neural cells, including impaired neural rosette formation, increased susceptibility to growth factor withdrawal, and deficits in mitochondrial respiration, are rescued in isogenic controls. Importantly, using genome-wide expression analysis, we show that a number of apparent gene expression differences detected between HD and non-related healthy control lines are absent between HD and corrected lines, suggesting that these differences are likely related to genetic background rather than HD-specific effects. Our study demonstrates correction of HD hiPSCs and associated phenotypic abnormalities, and the importance of isogenic controls for disease modeling using hiPSCs.
Stem Cell Reports 2017 MAR
EPHRIN-B1 Mosaicism Drives Cell Segregation in Craniofrontonasal Syndrome hiPSC-Derived Neuroepithelial Cells
Abstract
Abstract
Although human induced pluripotent stem cells (hiPSCs) hold great potential for the study of human diseases affecting disparate cell types, they have been underutilized in seeking mechanistic insights into the pathogenesis of congenital craniofacial disorders. Craniofrontonasal syndrome (CFNS) is a rare X-linked disorder caused by mutations in EFNB1 and characterized by craniofacial, skeletal, and neurological anomalies. Heterozygous females are more severely affected than hemizygous males, a phenomenon termed cellular interference that involves mosaicism for EPHRIN-B1 function. Although the mechanistic basis for cellular interference in CFNS has been hypothesized to involve Eph/ephrin-mediated cell segregation, no direct evidence for this has been demonstrated. Here, by generating hiPSCs from CFNS patients, we demonstrate that mosaicism for EPHRIN-B1 expression induced by random X inactivation in heterozygous females results in robust cell segregation in human neuroepithelial cells, thus supplying experimental evidence that Eph/ephrin-mediated cell segregation is relevant to pathogenesis in human CFNS patients.
Cell stem cell 2017 JAN
Recent Zika Virus Isolates Induce Premature Differentiation of Neural Progenitors in Human Brain Organoids.
Abstract
Abstract
The recent Zika virus (ZIKV) epidemic is associated with microcephaly in newborns. Although the connection between ZIKV and neurodevelopmental defects is widely recognized, the underlying mechanisms are poorly understood. Here we show that two recently isolated strains of ZIKV, an American strain from an infected fetal brain (FB-GWUH-2016) and a closely-related Asian strain (H/PF/2013), productively infect human iPSC-derived brain organoids. Both of these strains readily target to and replicate in proliferating ventricular zone (VZ) apical progenitors. The main phenotypic effect was premature differentiation of neural progenitors associated with centrosome perturbation, even during early stages of infection, leading to progenitor depletion, disruption of the VZ, impaired neurogenesis, and cortical thinning. The infection pattern and cellular outcome differ from those seen with the extensively passaged ZIKV strain MR766. The structural changes we see after infection with these more recently isolated viral strains closely resemble those seen in ZIKV-associated microcephaly.
Science Translational Medicine 2017 FEB
Tumor-homing cytotoxic human induced neural stem cells for cancer therapy
Abstract
Abstract
Engineered neural stem cells (NSCs) are a promising approach to treating glioblastoma (GBM). The ideal NSC drug carrier for clinical use should be easily isolated and autologous to avoid immune rejection. We transdifferentiated (TD) human fibroblasts into tumor-homing early-stage induced NSCs (h-iNSC(TE)), engineered them to express optical reporters and different therapeutic gene products, and assessed the tumor-homing migration and therapeutic efficacy of cytotoxic h-iNSC(TE) in patient-derived GBM models of surgical and nonsurgical disease. Molecular and functional analysis revealed that our single-factor SOX2 TD strategy converted human skin fibroblasts into h-iNSC(TE) that were nestin(+) and expressed pathways associated with tumor-homing migration in 4 days. Time-lapse motion analysis showed that h-iNSC(TE) rapidly migrated to human GBM cells and penetrated human GBM spheroids, a process inhibited by blockade of CXCR4. Serial imaging showed that h-iNSC(TE) delivery of the proapoptotic agent tumor necrosis factor-α-related apoptosis-inducing ligand (TRAIL) reduced the size of solid human GBM xenografts 250-fold in 3 weeks and prolonged median survival from 22 to 49 days. Additionally, h-iNSC(TE) thymidine kinase/ganciclovir enzyme/prodrug therapy (h-iNSC(TE)-TK) reduced the size of patient-derived GBM xenografts 20-fold and extended survival from 32 to 62 days. Mimicking clinical NSC therapy, h-iNSC(TE)-TK therapy delivered into the postoperative surgical resection cavity delayed the regrowth of residual GBMs threefold and prolonged survival from 46 to 60 days. These results suggest that TD of human skin into h-iNSC(TE) is a platform for creating tumor-homing cytotoxic cell therapies for cancer, where the potential to avoid carrier rejection could maximize treatment durability in human trials.
Methods in molecular biology (Clifton, N.J.) 2016 JAN
Multisystemic Disease Modeling of Liver-Derived Protein Folding Disorders Using Induced Pluripotent Stem Cells (iPSCs).
Abstract
Abstract
Familial transthyretin amyloidosis (ATTR) is an autosomal dominant protein-folding disorder caused by over 100 distinct mutations in the transthyretin (TTR) gene. In ATTR, protein secreted from the liver aggregates and forms fibrils in target organs, chiefly the heart and peripheral nervous system, highlighting the need for a model capable of recapitulating the multisystem complexity of this clinically variable disease. Here, we describe detailed methodologies for the directed differentiation of protein folding disease-specific iPSCs into hepatocytes that produce mutant protein, and neural-lineage cells often targeted in disease. Methodologies are also described for the construction of multisystem models and drug screening using iPSCs.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.